E10i-494
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
Ionizable lipid for LNP and nucleic-acid delivery research.
GVS-18-B6 is a biodegradable silicon-ether ionizable lipid reported for liver-directed mRNA delivery. The literature-verified structure contains a dimethylamino headgroup connected through a four-carbon linker to a silicon center bearing three cis-4-decenyl ether chains. In the cited study, GVS-18-B6 LNPs showed high mRNA encapsulation, an apparent LNP pKa of 6.15, preferential hepatic expression after intravenous administration, rapid tissue clearance, and favorable tolerability in the reported mouse and nonhuman-primate experiments. All formulation and performance values shown below are literature-reported study results, not specifications or guaranteed performance of the supplied lipid.
| CAS No. | Not available |
| Chemical Name | Lipid GVS-18-B6 |
| Synonyms | Lipid GVS 18 B6, GVS-18-B6 |
| SMILES | CCCCC/C=C\CCCO[Si](CCCCN(C)C)(OCCC/C=C\CCCCC)OCCC/C=C\CCCCC |
| Formula | C36H71NO3Si |
| M.Wt | 594.05 |
| Purity | ELSD-HPLC>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Holland R, Lam K, Jeng S, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano. 2024;18:10374-10387. |
| Component | mol% | Role |
|---|---|---|
| GVS-18-B6 | 54.6 | Ionizable lipid |
| DSPC | 10.9 | Helper phospholipid |
| Cholesterol | 32.8 | Sterol |
| PEG-conjugated lipid (identity not specified in article) | 1.6 | PEG lipid |
| Reported total | 99.9 | Source values retained |
The parent GVS-18-B6 lipid was reported as almost completely cleared from mouse liver within 6 hours after IV dosing.
EGFP mRNA LNP; IV; mouse; LC-MS · Figure 2 and text, pp. 10376-10377GVS-18-B6 LNPs were reported as well tolerated at doses up to 6 mg/kg, with little elevation in the measured ALT, AST, MCP-1 or IL-6 biomarkers.
Nonstimulatory siRNA LNP; IV; female BALB/c mice · Figure 3 and text, pp. 10377-10378After a 1 mg/kg IV infusion of hOTC mRNA LNP, strong hOTC expression was reported in liver, with substantially lower expression in spleen; the vast majority of GVS-18-B6 was degraded in liver within 24 hours.
hOTC mRNA LNP; 1 mg/kg; 60-minute IV infusion; cynomolgus monkeys · Figure 5A-C and text, pp. 10378-10379Weekly 0.25 mg/kg IV doses for five weeks produced comparable plasma hEPO profiles after doses 1 and 5, with no efficacy pattern indicative of accelerated blood clearance in the reported experiment.
hEPO mRNA LNP; 0.25 mg/kg; IV every 7 days × 5; cynomolgus monkeys · Figure 5D and text, pp. 10378-10379The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 16.8336 mL | 3.3667 mL | 1.6834 mL |
| 25 mg | 42.0840 mL | 8.4168 mL | 4.2084 mL |
| 50 mg | 84.1680 mL | 16.8336 mL | 8.4168 mL |
| 100 mg | 168.3360 mL | 33.6672 mL | 16.8336 mL |
| 250 mg | 420.8400 mL | 84.1680 mL | 42.0840 mL |
Contact our team with the catalog number and requested quantity.